Decipher Labs Limited has successfully concluded its Extraordinary General Meeting (EGM) held on February 12, 2026, with shareholders unanimously approving a key leadership appointment. The meeting was conducted through video conferencing from 11:00 AM to 11:18 AM, in compliance with regulatory guidelines.

Resolution Outcome

The company's shareholders approved the appointment of Mr. Dalavath Amar Singh (DIN: 02206249) as Director and Whole-Time Director through a special resolution. The voting results demonstrated strong shareholder support:

E-Voting Process

The electronic voting process was conducted in two phases to ensure maximum shareholder participation. Remote e-voting remained open from 9:00 AM on February 9, 2026, to 5:00 PM on February 11, 2026. Additionally, shareholders attending the EGM through video conferencing had the opportunity to vote during the meeting.

Regulatory Compliance

M/s. S.S. Reddy & Associates, Practicing Company Secretaries, served as the appointed scrutinizer for the electronic voting process. The scrutinizer was appointed by the Board of Directors on January 19, 2026, pursuant to Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shareholder Participation

The meeting recorded participation from 41 attendees through video conferencing, including one promoter group member and 40 public shareholders. The record date for determining voting eligibility was set as February 5, 2026, with the company having 30,080 total shareholders on record.

The successful completion of this EGM marks an important milestone in the company's governance structure, with the unanimous approval reflecting strong shareholder confidence in the proposed leadership appointment.

Decipher Labs Limited , a pharmaceutical company, has reported financial results for the quarter ended September 30, 2025, and announced a key executive appointment.

Financial Performance

The company reported a standalone loss before tax of Rs. 5.64 lakhs for the quarter ended September 30, 2025. On a consolidated basis, the loss before tax for the half-year period stood at Rs. 340.34 lakhs.

Key Financial Highlights (Consolidated)

Segment Performance

The company operates in two segments:

1. Manufacturing and Trading of Pharmaceutical drugs
2. Consultancy Services

For the half-year ended September 30, 2025, the Consultancy Services segment contributed significantly to the revenue, generating Rs. 656.24 lakhs, while the Manufacturing and Trading of Pharmaceutical drugs segment reported revenue of Rs. 67.50 lakhs.

Executive Appointment

Decipher Labs has appointed Mr. Dalavath Amar Singh as an Additional Director in the Executive category. The appointment is for a period of two years, subject to shareholder approval, with an annual remuneration of Rs. 6 lakhs.

Mr. Amar Singh brings operational experience in the pharmaceutical industry to the board. His expertise includes plant operations, team coordination, and production processes, which are expected to provide on-ground insights to the company's strategic decisions.

Balance Sheet Position

As of September 30, 2025, Decipher Labs reported:

• Total Assets: Rs. 2,376.02 lakhs
• Total Equity and Liabilities: Rs. 2,376.02 lakhs
• Equity Share Capital: Rs. 1,010.00 lakhs

Cash Flow

The company reported a net decrease in cash and cash equivalents of Rs. 200.76 lakhs for the half-year ended September 30, 2025, with the closing balance of cash and cash equivalents standing at Rs. 80.07 lakhs.

Decipher Labs continues to operate in the pharmaceutical and consultancy sectors. The appointment of Mr. Amar Singh may signal the company's focus on strengthening its operational capabilities.